DAL MASO, ALESSANDRO

DAL MASO, ALESSANDRO  

Università di Padova  

Mostra records
Risultati 1 - 20 di 29 (tempo di esecuzione: 0.065 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial 2025 Bonanno, LauraDal Maso, Alessandro + CLINICAL CANCER RESEARCH - -
Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis 2024 Pasello, GiuliaPavan, AlbertoDal Maso, AlessandroBonanno, LauraGuarneri, Valentina + FRONTIERS IN ONCOLOGY - -
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 2024 Bonanno, LauraZingone, FabianaBarberio, BrigidaDal Maso, AlessandroPasello, GiuliaDei Tos, Angelo PaoloFassan, MatteoSavarino, Edoardo VincenzoGuarneri, Valentina + THE ONCOLOGIST - -
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 2024 Pasello, GiuliaPavan, AlbertoPolo, ValentinaBonanno, LauraDal Maso, AlessandroGuarneri, Valentina + THE ONCOLOGIST - -
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis 2024 Bonanno, LauraDal Maso, AlessandroPavan, AlbertoPasello, GiuliaGuarneri, Valentina + FRONTIERS IN IMMUNOLOGY - -
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer 2024 Maso, Alessandro DalBonanno, LauraGuarneri, ValentinaPasello, Giulia + CANCER TREATMENT REVIEWS - -
The role of liver kinase B1 in small cell lung cancer: association with prognosis and tumor immune microenvironment features 2024 DAL MASO, ALESSANDRO - - -
Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients 2024 Bonanno, LauraDal Maso, AlessandroGuarneri, ValentinaPasello, Giulia + FRONTIERS IN IMMUNOLOGY - -
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 2023 Maso, Alessandro DalBrambilla, MartaPaggio, AngelaPasello, Giulia + JOURNAL OF THORACIC ONCOLOGY - -
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience 2022 Dal Maso, ADel Bianco, PNardo, GZulato, EBonanno, LPasello, GIndraccolo, S + JOURNAL OF THORACIC DISEASE - -
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 2022 Bonanno, LauraDal Maso, AlessandroZulato, ElisabettaPasello, GiuliaGuarneri, ValentinaConte, PierFrancoIndraccolo, Stefano + BRITISH JOURNAL OF CANCER - -
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments 2022 Sepulcri, MatteoSchiavon, MarcoMancin, EdoardoLunardi, FrancescaDal Maso, AlessandroBonanno, LauraCalabrese, FiorellaRea, FedericoGuarneri, ValentinaPasello, Giulia + CANCERS - -
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 2021 Dal Maso, A.Ferro, A.Pretelli, G.Frega, S.Menis, J.Pasello, G.Guarneri, V.Conte, P. F.Bonanno, L. + JOURNAL OF THORACIC ONCOLOGY - -
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 2021 Lorenzi, M.Dal Maso, A.Ferro, A.Scattolin, D.Indraccolo, S.Frega, S.Menis, J.Bonanno, L.Guarneri, V.Conte, P. F.Pasello, G. + JOURNAL OF THORACIC ONCOLOGY - -
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 2021 Bonanno, L.Dal Maso, A.Zulato, E.Fassan, M.Pasello, G.Guarneri, V.Calabrese, F.Rea, F.Indraccolo, S.Conte, P. F. + JOURNAL OF THORACIC ONCOLOGY - -
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors 2021 Marra, LudovicaBonanno, LauraBoscolo, AliceDal Maso, AlessandroBoscolo Bragadin, AndreaIndraccolo, StefanoZulato, Elisabetta + FRONTIERS IN ONCOLOGY - -
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 2021 Lorenzi, MartinaFerro, AlessandraScattolin, DanielaDal Maso, AlessandroIndraccolo, StefanoCalabrese, FiorellaBonanno, LauraConte, PierFrancoGuarneri, ValentinaPasello, Giulia + THE ONCOLOGIST - -
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 2021 Dal Maso, ALorenzi, MFerro, AScattolin, DIndraccolo, SFrega, SMenis, JBonanno, LCalabrese, FGuarneri, VConte, PPasello, G + FUTURE ONCOLOGY - -
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 2021 Boscolo Bragadin, AndreaZulato, ElisabettaAttili, IlariaDal Maso, AlessandroFrega, StefanoFassan, MatteoCalabrese, FiorellaPasello, GiuliaGuarneri, ValentinaConte, PierFrancoIndraccolo, StefanoBonanno, Laura + TRANSLATIONAL LUNG CANCER RESEARCH - -
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 2020 Dal Maso, A.Ferro, A.Lorenzi, M.Scattolin, D.Frega, S.Bonanno, L.Indraccolo, S.Calabrese, F.Guarneri, V.Conte, P. F.Pasello, G. + ANNALS OF ONCOLOGY - -